Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease

Amygdala atrophy is not homogeneous in preclinical Alzheimer's disease (AD). Tau pathology is associated with atrophy of specific amygdala subnuclei, specifically, the central, medial, cortical, and accessory basal subnuclei. Hippocampal and amygdala volume is not associated with tau in preclinical AD. Hippocampus and CA1-3 volume is reduced in preclinical AD, regardless of tau.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-09-10
DOI
https://doi.org/10.1002/alz.14235
Citations
17
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
6.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease

Lara Huyghe, Renaud Lhommel, Adrian Ivanoiu, Thomas Gérard et al.
17 citations
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
6.55
article

Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease

Lara Huyghe, Renaud Lhommel, Adrian Ivanoiu, Thomas Gérard, Bernard Hanseeuw, Lisa Quenon, Yasmine Salman, Laurence Dricot, Lise Colmant, Vincent Malotaux
article en
17 citations

Abstract

Amygdala atrophy is not homogeneous in preclinical Alzheimer's disease (AD). Tau pathology is associated with atrophy of specific amygdala subnuclei, specifically, the central, medial, cortical, and accessory basal subnuclei. Hippocampal and amygdala volume is not associated with tau in preclinical AD. Hippocampus and CA1-3 volume is reduced in preclinical AD, regardless of tau.

Alzheimer s & DementiaVol. 20(10)
Cliniques Universitaires Saint-Luc (BE), Harvard University (US), Massachusetts General Hospital (US), Walloon Excellence in Lifesciences and Biotechnology (BE), UCLouvain (BE)
U.S. Department of Defense, Alzheimer's Association, Bristol-Myers Squibb, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, Pfizer, Merck, Roche, Biogen, University of Southern California, AbbVie, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, Fondation Louvain, BioClinica, Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company, Northern California Institute for Research and Education, Fonds De La Recherche Scientifique - FNRS, Eisai, Fondation Saint Luc, Servier, H. Lundbeck A/S, IXICO, Fondation pour la Recherche sur Alzheimer, Walloon excellence in life sciences and biotechnology, National Institutes of Health, Genentech, GE Healthcare, Canadian Institutes of Health Research, Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
Good health and well-being
Openalex Percentile: Top 2%
Dementia and Cognitive Impairment Research
6.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.